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Influenza Antiviral Use for Persons at High Risk for Influenza 
Complications or Who Have Severe Influenza Illness
CDC is alerting clinicians to be fu lly aware o f the potentia l benefits o f influenza antiv ira l medications during 
this influenza season.
Summary:
Recent surveillance data indicate that many communities are reporting substantially increased influenza activity. This CDC Health 
Advisory is intended to re-emphasize the importance of considering antiviral medications for use in the treatment or prevention of 
influenza. The two prescription antiviral medications recommended for treatment or prevention of influenza include oseltamivir 
(Tamiflu®, Roche Laboratories, Nutley, NJ) or zanamivir (Relenza®, GlaxoSmithKline, Research Triangle Park, NC). These 
antiviral medications are also known as neuraminidase inhibitors. Recent studies suggest a considerable protective effect against 
complications associated with influenza when neuraminidase inhibitors are used for treatment. These benefits include reducing the risk of 
death among older adults hospitalized with laboratory-confirmed influenza. Because high levels of resistance to adamantane antiviral 
medications (rimantadine and amantadine) continue to be observed among circulating influenza A viruses, adamantanes are not 
recommended for treatment or prevention of influenza.
Background:
During this influenza season, a small increase in the number of influenza viruses resistant to oseltamivir has been observed in the United 
States. Among the 471 influenza A and B viruses tested during the 2007- 08 influenza season to date, 27 (5.7%) have been found to be 
resistant to oseltamivir, compared with 0.7% during the 2006-07 season. All of the oseltamivir-resistant viruses have been influenza A 
viruses of the H1N1 subtype; 8.7% of the 310 H1N1 viruses tested are resistant to oseltamivir. No resistance to oseltamivir has been 
observed among the 161 influenza A (H3N2) and influenza B viruses tested to date, and no antiviral resistance to zanamivir has been 
detected in any subtype.
Recommendations:
Given the low level of overall resistance to oseltamivir among circulating influenza viruses, the finding of resistance only in influenza A 
(H1N1) viruses, and no resistance to zanamivir, neuraminidase inhibitor medications continue to be recommended for the treatment 
and chemoprophylaxis of influenza. Antiviral treatment should begin within 48 hours of symptom onset if possible, but treatment should 
still be considered for persons who present more than 48 hours after illness onset if they have severe influenza illness or are at higher risk 
for severe complications from influenza. Oseltamivir is approved for treatment and prevention of influenza for persons 1 year and 
older, while zanamivir is approved for treatment of persons 7 years and older and prevention of influenza in persons 5 years and 
older. Enhanced surveillance for detection of oseltamivir-resistant influenza viruses is ongoing, and antiviral usage recommendations will 
be revised to account for changes in antiviral resistance trends as needed. Influenza A viral isolates from affected persons in institutional
outbreaks should be subtyped. Health care providers should contact their local or state public health department for assistance when an 
outbreak of influenza in an institutional setting (e.g., a long-term care facility) occurs. State health departments should consult with CDC 
about the need for antiviral resistance testing when influenza A (H1N1) viral isolates are obtained from outbreaks in institutional settings.
In some communities, circulating influenza virus strains during this influenza season are antigenically different from those contained in 
current influenza vaccines. Preliminary results from a rapid assessment of vaccine effectiveness suggest that currently available influenza 
vaccines provide some protection against influenza virus infection requiring medical care. However, the level of protection is likely to be 
lower than what is observed in seasons in which the vaccine strains are closely matched to circulating influenza virus strains. When 
influenza vaccine effectiveness is reduced, clinicians should be aware of the potential for appropriately vaccinated persons to develop 
influenza despite vaccination.
Because approximately 2 weeks is required to develop an optimal immune response to influenza vaccination, use of neuraminidase 
inhibitors for prevention of influenza during a confirmed influenza institutional outbreak should be considered for persons at higher risk for 
influenza complications and who were vaccinated within the previous 2 weeks. Persons who were vaccinated more than two weeks before 
a suspected influenza virus exposure, but who are less likely to develop protective immunity after vaccination (e.g., persons in long-term 
care facilities or persons with immunosuppression), can be considered for antiviral chemoprophylaxis when local influenza surveillance 
data indicate that influenza activity is high.
Clinicians should consider whether to recommend influenza antiviral treatment based on the severity of the patient's illness, the time since 
illness onset, local influenza surveillance data and influenza test results. Rapid diagnostic tests for influenza have good specificity, but are 
only moderately sensitive. Positive rapid tests are generally reliable when influenza activity is high in a community and are useful in 
deciding whether to initiate antiviral treatment. Negative rapid test results are less helpful in making treatment decisions. When local 
influenza activity is high, persons with severe respiratory symptoms or persons with acute respiratory illness who are at higher risk for 
influenza complications should still be considered for influenza antiviral treatment despite a negative rapid influenza test unless illness can 
be attributed to another cause. As reported in a previous HAN, persons with severe influenza illness should also be assessed for invasive 
bacterial co-infection, and appropriate antimicrobial therapy directed at potential bacterial pathogens, such as methicillin-resistant 
Staphylococcus aureus, might be necessary.
To reduce the substantial burden of influenza in the U.S., CDC continues to recommend a three-pronged approach: influenza 
vaccination, use of neuraminidase inhibitor antiviral medications when indicated for treatment or prevention, and use of other 
measures to decrease the spread of influenza, including promotion of hand hygiene, respiratory hygiene, cough etiquette, and 
staying home from work and school when ill. Clinicians in communities experiencing increased influenza activity should consider 
prescribing the neuraminidase inhibitor antiviral medications oseltamivir and zanamivir for the treatment of influenza patients or for 
prevention of influenza when indicated for institutional influenza outbreaks or for persons at high risk for complications from influenza 
who have contraindications to influenza vaccination.
For more information, please see the CDC website: http://www.cdc.gov/flu/professionals/antivirals/
If you have any questions about this Health Advisory, please call the Influenza Division, Epidemiology and Prevention Branch at 404-639­
3747.
After normal business hours, contact CDC's duty officer through the CDC Director's Emergency Operation Center (DEOC) at (770) 488­
7100.
The Centers fo r Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and in juries; enhances health decisions by providing credible inform ation on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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